Immuno-Oncology Essentials: Applications in Clinical Scenarios: A JCO Oncology Practice Supplement

As immune checkpoint inhibitors are used in a wider array of tumor types, the need for education about their optimal use and the management of immune-related adverse events (irAEs) grows as well. This case-based digital supplement to JCO Oncology Practice addresses the management of irAEs associated with immune checkpoint inhibitors through the incorporation of the Immuno-Oncology (IO) Essentials resources. These articles, written by multidisciplinary care teams, demonstrate the practical applications of the IO Essentials Care Step Pathways, patient action plans, and other materials in the context of challenging cases across tumor types.

Release date: February 11, 2020
Expiration date: February 11, 2021
Estimated time to complete: 1.0 hours
Fee: None

This activity is designed to help clinicians achieve specific learning objectives, which reflect the desired results of the education. Participants are encouraged to integrate what they learn from this activity into practice to improve patient care and outcomes.

Jointly provided by

image image image image

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net

Harborside
94 North Woodhull Road
Huntington, NY 11743
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: smcgullam@hbside.com

AIM With Immunotherapy Foundation
139 Waterside Circle
San Rafael, CA 94903
Voice: 916-706-0599
E-mail: sguild@aimatmelanoma.org

Terranova Medica, LLC
564 Vista Grande Drive
Colorado Springs, CO 80906
Voice/Fax: 877-276-4523
Email: tdavis@terranovamedica.com

© 2020, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

Faculty

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, Yale Comprehensive Cancer Center, New Haven, Connecticut

Anne C. Chiang, MD, PhD, Yale Comprehensive Cancer Center, New Haven, Connecticut

Lisa Kottschade, APRN, MSN, CNP, Mayo Clinic, Rochester, Minnesota

Yiyi Yan, MD, PhD, Mayo Clinic, Rochester, Minnesota

Laura S. Wood, RN, MSN, OCN, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Moshe C. Ornstein, MD, MA, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Casey Fazer, PA-C, Mayo Clinic, Rochester, Minnesota

Katharine A. Price, MD, Mayo Clinic, Rochester, Minnesota

Intended Participants

Target Audience:
Oncology care providers (including physicians, nurses, and pharmacists and other health care providers) who care for patients receiving immunotherapy for cancer.

Learning Objectives

  • Define immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy
  • Propose strategies to support patients experiencing side effects of ICI therapies
  • Customize the therapeutic support strategy for patients with cancer receiving ICI therapy based on patient goals, disease characteristics, patient characteristics, and experience during therapy
  • Engage the interdisciplinary team to optimize the management of irAEs associated with ICI therapy

Continuing Education

Certification

This activity is certified for credit by Annenberg Center for Health Sciences at Eisenhower.
39000 Bob Hope Drive, Dinah Shore Building, Rancho Mirage, CA 92270
Voice: 760-773-4500; Fax: 760-773-4513; E-mail: contactce@annenberg.net
© 2020, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

Statement of Credit

Participants who successfully complete this activity—which includes submitting a completed pre-test, submitting and scoring at least 70% on the post-test, and submitting a completed evaluation form—will be able to download a statement of credit.

To access the learning assessment and evaluation form, visit https://education.annenberg.net/5778

Accreditation and Designation Statements

image

Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

image

Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned for successful completion of this activity.

Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.

image

Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been assigned ACPE Universal Program #0797-9999-20-001-H01-P. This activity is designated for up to 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. This is a knowledge-based activity.

Disclosures

Commercial Support

This certified activity is supported by educational grants from Merck & Co., Inc and Myriad Genetics.

Relationships of Faculty and Planners

All individuals in a position to control the content of this activity (eg, planners, faculty, reviewers) must disclose all financial relationships with commercial interests that may have a bearing on its subject matter. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with its policies and procedures. Participants should assess the impact (if any) of the disclosed information on the educational value of the activity.

Faculty

Laura S. Wood, RN, MSN, OCN, reported a consulting or advisory role with Merck, Eisai, and EMD Serono; speakers' bureau for Bristol-Myers Squibb, Pfizer, Genentech/Roche, and Merck; and travel, accommodations, and expenses from Bristol-Myers Squibb, Pfizer, Merck, Genentech/Roche, Eisai, and EMD Serono.

Moshe C. Ornstein, MD, MA, reported consulting or advisory role with Pfizer, Eisai, and Exelixis; speakers' bureau for Exelixis and Bristol-Myers Squibb; and travel, accommodations, and expenses from Exelixis and Bristol-Myers Squibb.

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, reported speakers' bureaus for AstraZeneca, Genentech/Roche, Merck, and Bristol-Myers Squibb.

Anne C. Chiang, MD, PhD, reported a consulting or advisory role with Genentech/Roche, Genentech, AstraZeneca, Abbvie, Boehringer Ingelheim, and Bristol-Myers Squibb; research funding from OncoMed, Millennium, Onyx, Boehringer Ingelheim, Lilly, Bristol-Myers Squibb, Stem CentRx, and AstraZeneca; and travel, accommodations, and expenses from Genentech/Roche, AstraZeneca, and Abbvie.

Lisa Kottschade, APRN, MSN, CNP, reported a consulting or advisory role with Array BioPharma, Immunocore, and Annenberg Center-Eisenhower Health; and research funding (institutional) from Bristol-Myers Squibb and Novartis.

Yiyi Yan, MD, PhD, has nothing to disclose.

Casey Fazer, PA-C, has nothing to disclose.

Katharine A. Price, MD, has nothing to disclose.

Planner

Harborside staff have no potential conflicts of interest to disclose.

Lead Nurse Planner

Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Terranova Medica, LLC

Lisa Tushla, PhD, H(ASCP), has nothing to disclose.

Content Reviewer

Lee Schwartzberg, MD, is a consultant for Amgen, AstraZeneca, Genentech/Roche, and Pfizer.

Disclaimer

The opinions expressed in this activity are those of the faculty and do not represent an endorsement by the Annenberg Center for Health Sciences at Eisenhower of any therapeutic agent or approach to diagnosis or patient management.

Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 CA-BRN
  • 1.00 ANCC
Course opens: 
02/11/2020
Course expires: 
02/11/2021
Cost:
$0.00
Rating: 
5

Available Credit

  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 CA-BRN
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.